Gilead is already seeking approval for its long-acting HIV project lenacapavir in heavily treatment-experienced patients. But the big prize for the group would be the much larger treatment-naive population, where the therapy took a step forward last month with promising phase 2 data in combination with standard therapies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,